Some researchers have found a way to detect the spread of cancer-causing cells through a teaspoon of blood. Even they say that this method can be used to predict cancer will recur after treatment.
The team from Harvard Medical School and Massachusetts General Hospital using funds from a nonprofit group to test the method, which they do to 20 men with prostate cancer.
They found tumor cells circulating in all these patients, who are known to have tumors that do not spread, and low levels of cancer in patients with prostate gland, they were appointed three months earlier.
"They all are a group of patients who are usually in their bodies never found circulating tumor cells. So this method gives us very much information about the risks they face," said Sunithat Nagrath of Harvard, who led the study, as cited by the British news agency , Reuters reported.
"What all of these patients more susceptible to recurrence of their disease?" he questioned in a briefing during the meeting of the American Association for Cancer Research.
Nagrath said, his team will follow the development of these patients to see if the tumor recurrence in patients who have cancer cells in circulation. Such experiments may also one day serve as a complete blood examination examination prostate specific antigen or PSA, by searching a protein made only by prostate cells, and which can indicate cancer.
According Nagrath, 200 inspection team were able to detect circulating tumor cells from a teaspoon of blood drawn from a patient with cancer.
Prostate cancer is the leading killer cancer for men after lung cancer. However, this disease often develops slowly, and the doctors did not believe any man who has the most deadly types of cancer and which men are most likely to spread or recurrence of cancer.
The researchers find tumor cells circulating in the blood one day and nine days after he underwent removal of all prostate cancers. The process is then repeated again in three months later.
They found the cells in 42 percent of patients, and in 64 percent of patients with advanced prostate cancer. These cells could not be found immediately after surgery, but reappeared in some patients.
Would be important to follow the development of these men to see how well their condition, and whether patients with more circulating cells facing worse conditions.
He also said that trials may be useful for monitoring patients who are referred to therapeutic target, which affects the cancer cells with a particular genetic mutation.
"With blood tests you can take a sample of patients each day to see if the genotype changed,"
0 comments:
Post a Comment